Open AccessManagement of the Gastrointestinal System Bleeding Caused by Direct-Acting Oral Anticoagulants
Author(s) -
Şencan Acar,
Ahmet Tarık Eminler
Publication year - 2021
Publication title -
deneysel ve klinik tıp dergisi/journal of experimental and clinical medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.103
H-Index - 3
eISSN - 1309-4483
pISSN - 1309-5129
DOI - 10.52142/omujecm.38.si.gastro.4
Subject(s) - rivaroxaban , medicine , dabigatran , edoxaban , apixaban , direct thrombin inhibitor , atrial fibrillation , gastrointestinal bleeding , pulmonary embolism , stroke (engine) , heparin , anesthesia , intensive care medicine , warfarin , cardiology , mechanical engineering , engineering
Direct-acting oral anticoagulants include dabigatran, which is a thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, which are anti-Xa agents. These are administered in the secondary prophylaxis and treatment of venous thromboembolism (VTE) and pulmonary embolism (PE), in the prophylaxis of VTE that may develop after major elective orthopedic surgery, in reducing stroke and systemic embolism that may occur in non-valvular atrial fibrillation, whereas its use in acute coronary syndrome is still controversial. Although it is specified that direct-acting oral anticoagulants are as effective as heparin therapy and reduce the risk of bleeding due to all causes, many important studies have also reported that they increase the risk of gastrointestinal system (GIS) bleeding.